Drugs / ABT-301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07244705 | Nov 2025 → Apr 2028 expected | colorectal cancer | Anbogen Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABT-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07244705 ↗ |
| Action | Inhibit | “ABT-301 is an oral histone deacetylase inhibitor (HDACi) administered in capsule form once daily (QD ±3 hours) or every 12 hours (Q12H ±3 hours, with at least 9 hours between...” NCT07244705 ↗ |
| Route | Oral | “ABT-301 is an oral histone deacetylase inhibitor (HDACi) administered in capsule form” NCT07244705 ↗ |